Identification of optimal delivery systems for the Nucleic Acid Based Drugs and study of the action mechanisms in some models of human tumoral and inflammatory pathologies
Principal Investigator: Mario Grassi
For hepatocellular carcinoma, prostate adenocarcinoma, coronary restenosis, abdominal aortic aneurism, inflammatory bowel and lung diseases, a significant improvement in the efficacies of the therapeutic approaches so far available is urgently required. The use of “nucleic acid based drugs” (NABDs), a novel and emergent class of molecules, is considered very promising. However, a limitation in NABD use as drugs depends on the lack of optimal delivery systems able to minimize NABD degradation in the biological fluid and allow the targeting to the diseased tissue.
The aim of this project is to develop novel delivery systems for NABDs, appropriate for the considered human pathologies. Our approach will take into consideration the different problematics related to the engineering field, but also chemical, pharmaceutical and biomedical filed. Nine University groups will take part to the project together with eigtheen other non-University research groups.
|01. UNITS||Mario Grassi||Read More
|02. UNISA||Gaetano Lamberti|| Read More
|03. UNIPV||Piersandro Pallavicini|| Read More
To individuate an efficient therapy for hepatocellular carcinoma we will study the delivery NABDs, developed by Unit 01, by means of nanovectors based on gold asymmetric branched nanoparticles (ABN) and on spherical magnetite nanoparticles (MNP).
|04. UNINA||Stefano Guido|| Read More
The activity is focused on the study of the interaction between human blood cells, in particular red blood cells, and either vessel walls or micro/nano particles, developed by the other Unit, for NABD delivery.
|05. CNR NA||Domenico Larobina||Read More
The aim is to support the other research units involved in the project with appropriate structural information on the gel systems employed in the release of NABD. For this specific purpose, we will adopt both mechanical and spectroscopic techniques. Such characterizations represent a useful support to set up the specific polymeric device able to release NABDs.
|06. UNIPA1||Gennara Cavallaro||Read More
We will produce and characterize NABD delivery systems appropriate for the pathological conditions proposed by Units 01, 02 and 08; in particular we will evaluate:
|07. UNIPA2||Valerio Brucato||Read More
We will prepare polymeric scaffolds (made of PLLA and/or PLLA/PLA mixtures) pre-angiogenized as from proprietary patent, and will carry out advanced “in vitro” tests on the NABD release. PLLA scaffold, featuring a pseudo-vascular structure, prepared as for the proprietary patent, will be cultured with mixed population of mesenchymal cells (to promote the ECM formation) and tumoral cells (of interest for the pathologies of this project) showing different metastatic strenght to generate structure close to a tumoral mass. By the “pseudo-vascular” system an “in vitro” evaluation of the performance shown by the specific NABDs dose release on tumoral mass will be evaluated.
|08. UNIFG||Sante Di Gioia||Read More
In order to tackle the limits of available therapeutic approaches in severe asthma, we plan to use NABDs targeting GM-CSF, HMGB1, and TGF-ß1. In collaboration with Unit I appropriate NABDs will be selected; with support of Units 02, 05 and 06 adequate delivery systems will be developed.
|09. POLIMI||Davide Manca||Read More
Our contribution consists of the modelling service for the other research Units. The modeling will be devoted to two different topics:
For both topics, a relevant model will be the one developed by Unit 07
Articles published on international journalsRead More
Computers & Chemical Engineering, 84 , pp. 394-408, 2016, ISSN: 00981354.
12th International Symposium on Process Systems Engineering and 25th European Symposium on Computer Aided Process Engineering, 37 , pp. 77–84, 2015, ISSN: 15707946.
Sorafenib in mice - A Pharmacokinetic study Journal Article
Chemical Engineering Transactions, 43 , pp. 283-288, 2015, ISBN: 978-88-95608-34-1.
ADMET & DMPK, 2 (2), pp. 80–97, 2014, ISSN: 1848-7718.
Translational Medicine @ UniSa, 7 , pp. 18–22, 2013, ISSN: 2239-9747.
Conference ProceedingsRead More
PHARMACOKINETICS OF REMIFENTANIL: METABOLISM AND MODELING Inproceedings
1st International Congress of Controlled Release Society - Greek Local Chapter, 2015.
Bioaccessibility of active principles: an in-vitro reproduction of human physiology Inproceedings
Proccedings of 4th International Conference on Food Digestion, pp. 1–1, 4th International Conference on Food Digestion, Naples, Italy, 2015.
In-vitro models of the gastro-intestinal tract for pharmaceutical and nutritional purposes Inproceedings
Proceedings of CHISA 2014/PRES 2014, pp. 2–2, CHISA 2014, Prague, Czech Republic, 2014.
AN IN VITRO MODEL TO REPRODUCE THE MECHANICS AND THE ABSORPTION IN THE GASTROINTESTINAL TRACT Inproceedings
13th European Symposium on Controlled Drug Delivery, pp. 1–2, ESCDD 2014, Egmond aan Zee, The Netherlands, 2014.
Simulation of gastrointestinal tract: mechanics and absorption Inproceedings
Proceedings of PBP 2014, pp. 3–4, PBP 2014, Lisbon, Portugal, 2014.
I meeting 5-6 February 2013 – Trieste
Download the flier: I meeting PRIN
II meeting 27-29 September 2013 – Palermo
III meeting 20-21 June 2014 – Ustica
Download the flier: III meeting PRIN
IV meeting 2-3 February 2015 – Milano
Download the flier: IV meeting PRIN
V meeting 14-15 September 2015 – Salerno
Go to the dedicated page: Workshop – New trends in gene therapy
Download the flier: V meeting PRIN
VI meeting 24-25 May 2016 – Trieste
Flyer and program:
Download the flier: VI meeting PRIN